EZH2 and neoplasm: Blocking EZH2 in orthotopic, murine, KPC tumors, treated with MEK and CDK4/6 inhibitors, subsequently led to an increase in intra-tumoral CCL2 and CXCL9/10 production and was associated with NK- and T-cell influx and anti-tumor responses [130].